TARS - CIK 0001819790
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $451.36M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $451.36M | +146.7% |
| FY 2024 | $182.95M | +948.6% |
| FY 2023 | $17.45M | -32.4% |
| FY 2022 | $25.82M | -54.7% |
| FY 2021 | $57.03M | - |
| FY 2020 | $0.00 | - |
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $451.36M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Tarsus Pharmaceuticals, Inc.'s revenue grew from $0.00 to $451.36M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.